A carregar...
Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers
Pancreatic cancer is a disease with limited therapeutic options. Resistance to chemotherapies poses a significant clinical challenge for pancreatic cancer patients and contributes to a high rate of recurrence. Here we showed that oncogenic KRAS, a critical driver of pancreatic cancer, promotes metab...
Na minha lista:
| Publicado no: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7185043/ https://ncbi.nlm.nih.gov/pubmed/31911550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1363 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|